The Fly | SILO

Today

Silo Pharma prices $11.7M at-the-market offering at $6.45 per share

SILO

8:10 AM

Over a week ago

Psychedelic: Helus Pharma reports FY26 financial results

Jul 2, 9:56 AM

Silo Pharma engages Resyca to conduct a robustness study for SPC-15 delivery

SILO

Jun 29, 4:48 PM

Psychedelic: Definium soars on study results for LSD-based depression treatment

Jun 25, 10:14 AM

Silo Pharma reports positive stability data for stress treatment SPC-15

SILO

Jun 23, 9:25 AM

Silo Pharma regains compliance with Nasdaq min bid price requirement

SILO

Jun 18, 8:26 AM

Silo Pharma Inc trading halted, news pending

SILO

Jun 2, 7:50 PM

Psychedelic: Jefferies initiates Compass Pathways with a Buy rating

May 7, 10:26 AM

Silo Pharma files provisional patent for ibogaine-based therapeutics

SILO

May 7, 9:55 AM

Psychedelic: FDA awards Compass Pathways priority review voucher

Apr 30, 10:18 AM

Silo Pharma expands into AI technology with Qwikagents asset purchase

SILO

Apr 22, 5:08 PM

Psychedelic: AtaiBeckley reports publication of BPL-003 study results

Apr 9, 10:57 AM

Silo Pharma gets European Patent Office allowance for PTSD prevention therapy

SILO

Apr 6, 4:17 PM

Silo Pharma announces $1M share repurchase program

SILO

Feb 23, 4:35 PM

Silo Pharma receives Notice of Allowance in Japan for SPC-15

SILO

Feb 18, 8:33 AM

Silo Pharma executes LOI with Allucent for Phase 1 development of SPC-15

SILO

Dec 30, 8:31 AM

Psychedelic: Clearmind reports results from first cohort in AUD trial

Nov 20, 12:00 PM

Silo Pharma partners with Allucent for planned FDA IND application for SPC-15

SILO

Nov 17, 8:06 AM

Silo Pharma selects AlphaLedger's T12 Fund for tokenized RWA investments

SILO

Oct 29, 8:29 AM

Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial

Oct 23, 11:18 AM

Silo Pharma provides update on SPC-15 advancement, digital asset program

SILO

Oct 23, 8:48 AM

Psychedelic: PharmAla launches portal for MDMA prescribers, therapists

Oct 9, 10:52 AM

Silo Pharma announces initial Bitcoin purchase

Oct 8, 8:47 AM

Silo Pharma acquires ResearchCoin crypto tokens

SILO

Oct 6, 8:31 AM

Silo Pharma prices 2.86M shares at 87.5c in registered direct offering

SILO

Sep 30, 8:31 AM

Strategic Academic Partnerships: Collaborations with top-tier research institutions like Columbia University and University of Maryland Baltimore lend scientific credibility and access to advanced R&D.

Targeting High-Unmet Neurological Needs: Focus on severe neurological and mental health disorders such as Alzheimer's, Parkinson's, and PTSD addresses significant market opportunities with limited current treatment options.

Innovative Drug Delivery Platforms: Development of novel delivery systems, including peptide-based delivery for targeted CNS therapeutics, aims to improve efficacy and patient outcomes.

Clinical Development Failure Risk: Silo Pharma's product candidates are in early stages of development and may not successfully complete clinical trials or obtain regulatory approval, which would materially harm its business.

Regulatory Approval Uncertainty Risk: The company operates in a highly regulated environment, and its psychedelic-based therapies face unique and stringent regulatory pathways, particularly concerning controlled substances, making approval uncertain and potentially lengthy.

Significant Capital Needs Risk: Silo Pharma will require substantial additional capital to fund its research and development programs and operations, which may not be available on favorable terms or at all, leading to potential delays or cessation of development.